LitAlert ~~ GeneLit.com

    • PARP Inhibitors Show Frontline Prostate Cancer Benefit; Conflicting Biomarker Data Raise Questions.
    • Hopkins C.
    • Precision Oncology News. Disease Areas. Cancer. 2022 Feb 17.
    • Conference report
    • Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
    • Vanderstichele A, Loverix L, Busschaert P, Van Nieuwenhuysen E, Han SN, Concin N, Callewaert T, Olbrecht S, Salihi R, Berteloot P, Neven P, Lambrechts D, Van Gorp T, Vergote I.
    • Gynecol Oncol. 2022 Feb 14:S0090-8258(22)00073-7. doi: 10.1016/j.ygyno.2022.01.034. Epub ahead of print.